Drug companies have a job to do and so does Health Canada. When the relationship becomes murky, the public are at risk.
Articles on Clinical trials
Displaying 121 - 140 of 224 articles
There is no doubt a regulated market for access to medicinal cannabis is safer, but if cannabis-based products were allowed to bypass efficacy trials, there’s a potential cost to patient safety.
Participants of clinical trials can easily communicate online, which poses a big problem for medical researchers.
Not all drug development needs to start from scratch. Sometimes researchers discover that a drug developed for one disease can be used for another. Here a cancer drug may show promise for dementia.
Asthma affects around 339 million people worldwide. A new drug promises to lower risks of asthma attack and may eventually allow patients to reduce their dependence on steroids.
A new agency and money for drugs for rare diseases are only very partial steps on the road towards what Canada really needs: a national pharmacare plan.
Clinical trials can assess impact of a medication on a disease. The ideal design is ‘blind’ – when the researchers and participants do not know who is assigned to the different treatments.
People with Down syndrome are at much higher risk of dementia than the general population. Knowing when cognitive changes start is critical for developing new drugs.
These four “natural” therapies for depression have rigorous, peer-reviewed scientific studies to support their use.
Alzheimer’s disease affects many people under the age of 65. The ‘young-onset’ version of the disease is often misdiagnosed as depression or dismissed as a midlife crisis.
A large trial to test whether rebooting the immune system will help patients with Crohn’s disease has just begun.
The strengths of blockchain technologies could help address the weaknesses of health care systems to store and secure medical records.
An autoimmune disease called vitiligo causes white spots to appear on the body, in some cases completely erasing an individual’s pigmentation. But a new therapy is on the horizon.
Clinical trials involving probiotics are failing to report on the safety and harms of these treatments.
As medicines, not all cannabis products are created equal.
Stating a majority of people won’t benefit from a vaccine ignores the purpose of immunisation programs.
African countries should be looking to initiate or host more clinical trials to improve the continent’s health systems.
You should be aware of the amount of genetic information you might disclose in a research study – and what the benefits and risks will be.
In this clinical trial, the first of its kind, physicians explore whether directly applying a ‘good’ strain of bacteria to the skin can heal eczema
Study of the “memory centres” of the brain in adults offers hope for detecting Alzheimer’s disease earlier – before the onset of memory loss.
Top contributors
-
Professor and Director of the Stoneygate Centre for Excellence in Empathic Healthcare, University of Leicester
-
Professor of Pharmaceutical Chemistry, Macquarie University
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Epidemiologist, Cochrane
-
Head of School and Dean of Pharmacy, University of Sydney
-
Professor of medicine, epidemiology & biostatistics, and philosophy, Western University
-
Professor of Immunology, RMIT University
-
Professor of Biostatistics and Epidemiology, Adelaide University
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Senior Lecturer Biostatistics and Data Management, The University of Queensland
-
Membre du comité d'éthique de l'Inserm, Inserm
-
Biostatistician, The University of Melbourne
-
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney
-
Professor of Law, Villanova University
-
Professor, UNSW